RB3000

RB3000 is a preclinical-stage therapeutic candidate developed by Alveolus Biomedical for the treatment of bronchopulmonary dysplasia (BPD). While Alveolus Biomedical is primarily known for its focus on inhaled therapies and alveolar regeneration, RB3000 is distinguished by its oral tablet formulation. BPD is a chronic lung disease that typically affects premature infants who require oxygen therapy, leading to arrested lung development and inflammation. RB3000 is intended to intervene in the disease process to improve lung function or promote tissue repair, although its specific molecular target and mechanism of action remain undisclosed.